Scale and Capacity Sofinnova Investments manages substantial assets with approximately $4.6B under management as of March 31, 2026, indicating strong deal flow potential and capacity to co-invest in large rounds, which is appealing for late-stage collaborations and syndication opportunities.

Healthcare Focus As a healthcare investment firm funding biotech, medtech and digital health ventures, Sofinnova frequently backs early to growth-stage companies, presenting ongoing sales opportunities in therapeutic platforms, clinical development tools, and regulatory strategy services.

Global Footprint Sofinnova operates in both the U.S. and Europe, suggesting readiness for cross-border partnerships, international market access services, and global clinical development and commercialization support.

Active Investment Activity Recent notable financings in 2025–2026 include investments in City Therapeutics, Coultreon Biopharma, Expedition Therapeutics, and One Biosciences, signaling a continued appetite for innovative biotech deals and potential co-investment or portfolio collaboration.

Financial Leverage With a recent capital raise of €1.2B for medtech, biotech, and digital health investments and revenue in the tens of millions, Sofinnova demonstrates substantial funding capacity and potential for strategic partnerships, advisory services, or platform technology licensing.